Itolizumab is under clinical development by Biocon and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Biocon’s stock jumped on December 24 after the United States Food and Drug Administration (USFDA) and the European Union ...

Biocon shares had gained earlier in the day after the company and its European partner Zentiva received a decentralised ...

The Nifty Pharma index closed 1.01 per cent at 23241.15. Benchmark NSE Nifty50 index ended down 168.5 points at 23644.9, ...

The rise in Biocon share price came after it announced that the company and its European partner, Zentiva, have received a ...

Biocon Ltd is quoting at Rs 352.1, up 1.63% on the day as on 12:49 IST on the NSE. The stock is up 42.35% in last one year as compared to a 9.51% jump in NIFTY and a 36.31% jump in the Nifty Pharma ...

The European Medicines Agency’s (EMA) Committee for Medicinal Use Products (CHMP) recently recommended approval of six new biosimilars.

Bangalore: Biocon and its European partner, Zentiva, have received a Decentralized Procedure (DCP) approval for its complex ...

Biocon Ltd, in collaboration with Zentiva, has obtained EU approval for the complex formulation Liraglutide, a generic ...

Biocon and Zentiva gain EU approval for generic Liraglutide, marking milestone in expanding complex generic medication ...

Bengaluru: Biocon has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from ...

Biocon Limited, alongside its European partner Zentiva, has successfully obtained approval for their generic version of ...